Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences reported fiscal Q1 2026 net sales of $250.2 million, essentially flat year over year, while profitability declined. Net earnings were $7.5 million versus $9.4 million a year ago, and diluted EPS fell to $0.41 from $0.49. Adjusted diluted EPS was $0.61 compared with $0.73, and Adjusted EBITDA was $28.4 million versus $29.8 million.
The Core Nutritional segment generated $204 million in net sales, down 3% year over year but up 7% sequentially, with 404,000 active customers, a 12% annual decline yet 4% sequential growth. Hiya posted $32 million in net sales, down 13% year over year, while Rise Wellness net sales surged to $14 million, up 741% year over year.
USANA ended the quarter with $163 million in cash and $14 million of debt. Management reiterated full‑year 2026 guidance, including consolidated net sales of $925 million to $1.0 billion, net earnings of $20 million to $27 million, diluted EPS of $1.11 to $1.45, and Adjusted EBITDA of $101 million to $109 million.
USANA Health Sciences director Timothy E. Wood reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into 1,057 shares of common stock, reflecting a derivative exercise with no cash purchase.
On the same date, 264 common shares were disposed of at $19.24 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market. Following these transactions, Wood directly held 10,613 shares of USANA common stock.
USANA Health Sciences director Frederic J Winssinger exercised restricted stock units into common stock, acquiring 1,057 shares. Following this transaction, he directly holds 8,101 shares of USANA common stock. Each restricted stock unit represents a contingent right to receive one share, with vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director J. Scott Nixon reported exercising 1,057 restricted stock units into an equal number of USANA common shares on April 23, 2026. Following this transaction, he directly holds 9,813 shares of common stock. Each restricted stock unit represented a right to receive one USANA share, and the units vested in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Gilbert A. Fuller exercised 1,057 restricted stock units into common stock. On April 23, 2026, 1,057 RSUs converted into 1,057 shares of USANA common stock at a stated price of $0.00 per share. After the transaction, he directly holds 1,057 common shares and no remaining RSUs under this grant.
Each restricted stock unit represented a contingent right to receive one share of common stock, with the grant vesting in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Peggie Pelosi reported routine equity compensation activity involving restricted stock units and common shares. On April 23, 2026, 1,057 restricted stock units were exercised into 1,057 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 668 common shares were disposed of at $19.24 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Pelosi directly held 5,364 shares of USANA common stock.
USANA Health Sciences director John Turman Fleming exercised 1,057 Restricted Stock Units into Common Stock on April 23, 2026. The RSUs converted into 1,057 shares of USANA common stock, increasing his directly held position to 6,680 shares after the transaction. Each RSU represented a contingent right to receive one share of common stock, with this grant vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Xia Ding reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into common stock, reflecting a derivative exercise tied to prior awards. To cover tax obligations, 391 shares of common stock were withheld and disposed of at $19.24 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Xia Ding directly held 7,641 shares of USANA common stock.
USANA Health Sciences is holding a virtual Annual Meeting on May 20, 2026, at 11:00 AM MDT to let shareholders vote online. Holders of 18,456,935 common shares as of March 16, 2026 can participate using a 16-digit control number.
Shareholders will elect eight directors, ratify KPMG LLP as independent auditor for Fiscal Year 2026, and cast an advisory vote on executive compensation. The Board recommends voting FOR all three items and highlights strong governance practices, including a majority of independent directors, a Lead Independent Director, stock ownership guidelines, a clawback policy, and prohibitions on pledging or hedging USANA stock.